UBS Group’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

UBS Group’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-3	Closed	-$3K	–	9530
2014 Q4	$3K	Buy	+3	New	+$2.68K	﹤0.01%	9291

Other funds holding ONCT

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

UBS Group's ONCT Position: Q4 2024 in Review

UBS Group sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 1,221 shares — an estimated $1.61K sold.

UBS Group first reported a position in ONCT in Q4 2014 and held it in 38 quarters. The position peaked at $692K in Q3 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

UBS Group reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
UBS Group sold 1,221 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $1.61K.
UBS Group first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2014 and held it in 38 quarters.
UBS Group's Oncternal Therapeutics, Inc. Common Stock position peaked at $692K in Q3 2021.
4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.

Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.